NT5E and familial pancreatic carcinoma: We also verified in tumors at PDAC stage that pancreatic cancer cells had reduced Myosin II activity when tumors were treated with CD73 blocking antibody, with no effects on CAFs (Fig. 6, I and J, and fig.